Mei Mei Hu
Founder chez VAXXINITY, INC.
Fortune : 51 M $ au 31/03/2024
Postes actifs de Mei Mei Hu
Sociétés | Poste | Début | Fin |
---|---|---|---|
VAXXINITY, INC. | Director/Board Member | 01/01/2014 | - |
Chief Executive Officer | 01/01/2014 | - | |
Founder | 01/01/2014 | - | |
President | 01/01/2014 | - | |
UNITED BIOPHARMA INC | Director/Board Member | 01/03/2020 | - |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Chief Executive Officer | 01/03/2020 | - |
Historique de carrière de Mei Mei Hu
Anciens postes connus de Mei Mei Hu
Sociétés | Poste | Début | Fin |
---|---|---|---|
Shen Lian Biotechnology Co. Ltd. | Director/Board Member | 01/01/2010 | 01/01/2014 |
United Neuroscience LLC | Director/Board Member | 01/10/2014 | - |
Formation de Mei Mei Hu
University of Pennsylvania | Undergraduate Degree |
Harvard Law School | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Taïwan | 2 |
Chine | 2 |
Opérationnelle
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Founder | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
VAXXINITY, INC. | Health Technology |
Entreprise privées | 4 |
---|---|
United BioPharma, Inc.
United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Health Technology |
United Neuroscience LLC | |
Shen Lian Biotechnology Co. Ltd. |
- Bourse
- Insiders
- Mei Mei Hu
- Expérience